AI-generated research brief — verify at source
Oral Alixorexton Produces Large Wakefulness Gains in Narcolepsy Type 1 Phase 2 Trial
Once-daily oral alixorexton, a selective orexin 2 receptor agonist, produced placebo-corrected improvements in mean sleep latency on the Maintenance of Wakefulness Test of 22.2 minutes (95% CI 17.2–27.2) at the 4 mg dose, 24.1 minutes (95% CI 19.0–29.1) at 6 mg, and 26.0 minutes (95% CI 21.0–31.0) at 8 mg after six weeks of treatment in adults with narcolepsy type 1. All three doses achieved statistical significance, and the magnitude of improvement was consistent with clinically meaningful gains in sustained wakefulness.
What Was Studied
This trial investigated whether alixorexton, an oral orexin 2 receptor (OX2R) agonist, could safely and meaningfully improve wakefulness — measured as mean sleep latency on the Maintenance of Wakefulness Test — in people with narcolepsy type 1, a condition characterised by severe daytime sleepiness and cataplexy caused by loss of orexin-producing neurons.
How It Was Studied
The Vibrance-1 study was a randomised, double-blind, placebo-controlled phase 2 trial enrolling 92 adults aged 18 to 70 years with confirmed narcolepsy type 1 — diagnosed according to the International Classification of Sleep Disorders, Third Edition, and verified by overnight polysomnography combined with either the Multiple Sleep Latency Test or cerebrospinal fluid hypocretin-1 measurement. Participants were recruited from 46 hospitals and private research centres across the United States, Europe, and Australia, and were assigned in equal proportions to receive alixorexton at 4 mg, 6 mg, or 8 mg once daily, or placebo, for six weeks. Randomisation was stratified by region and baseline weekly cataplexy rate. An optional seven-week open-label extension followed the blinded period. The sponsor, investigators, and participants all remained masked throughout the double-blind phase.
What Was Observed
- All three alixorexton doses produced large, statistically significant improvements in sustained wakefulness compared with placebo. Placebo-corrected gains in mean sleep latency were approximately 22 minutes for the 4 mg dose (22.2 min, 95% CI 17.2–27.2; adjusted p=0.0099) and approximately 24–26 minutes for the 6 mg and 8 mg doses (24.1 min, 95% CI 19.0–29.1, and 26.0 min, 95% CI 21.0–31.0; both adjusted p<0.0001), indicating a dose-related pattern of effect.
- The contrast between treated and untreated participants was stark in absolute terms: observed mean sleep latency at week 6 was only 2.3 minutes (SD 2.7) in the placebo group, compared with 24.0 minutes (SD 8.7), 25.9 minutes (SD 9.4), and 28.2 minutes (SD 11.4) in the 4 mg, 6 mg, and 8 mg groups respectively, reflecting near-normal wakefulness capacity in many treated participants.
- The most common treatment-emergent adverse event was pollakiuria (frequent urination), affecting 55% of alixorexton-treated participants. Other adverse events occurring in at least 5% of treated participants and more often than placebo included insomnia (28%), salivary hypersecretion (25%), micturition urgency (14%), blurred vision (14%), and hyperhidrosis (7%). These effects are consistent with physiological consequences of OX2R activation rather than off-target toxicity.
Why This Matters
Narcolepsy type 1 results directly from the loss of orexin signalling, making OX2R agonism a mechanistically targeted therapeutic approach aimed at the underlying neurological deficit. This trial demonstrates that selective pharmacological restoration of OX2R activity through an oral agent can produce large, objectively measured improvements in wakefulness, supporting the rationale that this drug class may address the core pathophysiology of the condition. The authors conclude these findings justify advancing alixorexton into phase 3 evaluation.
How to Read This Result
Although the effect sizes are large and confidence intervals are narrow, this remains a small, short-duration phase 2 trial (N=92 over six weeks), and the findings should be considered hypothesis-confirming rather than definitive, pending larger and longer phase 3 studies.
Limitations
The trial enrolled only 92 participants across four arms, limiting statistical power and the reliability of safety frequency estimates. The double-blind treatment period spanned just six weeks, which is insufficient to assess whether wakefulness gains are maintained over time or to detect rare adverse events. As a phase 2 study, it was not designed to provide the confirmatory efficacy evidence required for regulatory decision-making, and safety data beyond the optional seven-week open-label extension remain unavailable.